INNATE PHARMA CLINICAL DATA FEATURED AS ORAL PRESENTATIONS AT TWO MAJOR UPCOMING ONCOLOGY CONFERENCES
Marseille, France, November 2, 2018, 07:00 AM CET
Innate Pharma SA (the "Company" - Euronext Paris: FR0010331421 - IPH) today announced that new data from ongoing clinical trials evaluating monalizumab, partnered with AstraZeneca/MedImmune, and first-in-class antibody, IPH4102, will be presented at the SITC[1] 2018 Annual Meeting in Washington D.C., USA, November 7-11, 2018 and at ASH[2] 2018 Annual Meeting in San Diego, USA, December 1-4, 2018, respectively.
SITC 2018:
ASH 2018:
Innate Pharma is also taking part in many other scientific congresses, listed below:
For the full schedule of each event, please visit the "Events" section on Innate Pharma's website.
About Innate Pharma:
Innate Pharma S.A. is a fully integrated oncology-focused biotech company dedicated to improving treatment and clinical outcomes for patients through therapeutic antibodies that harness the immune system to fight cancer.
Innate Pharma's commercial-stage product, Lumoxiti, in-licensed from AstraZeneca, was approved by the FDA in September 2018. Lumoxiti is a first-in class specialty oncology product for hairy cell leukemia (HCL). Innate Pharma's broad pipeline of antibodies includes several first-in-class clinical and preclinical candidates in cancers with high unmet medical need.
Innate Pharma has pioneered the discovery and development of checkpoint inhibitors, with a unique expertise and understanding of Natural Killer cell biology. This innovative approach has resulted in major alliances with leaders in the biopharmaceutical industry including Bristol-Myers Squibb, Novo Nordisk A/S, Sanofi, and a landmark and multi-products partnership with AstraZeneca/MedImmune.
Based in Marseille, France, Innate Pharma is listed on Euronext Paris.
Learn more about Innate Pharma at www.innate-pharma.com.
Information about Innate Pharma shares:
ISIN code Ticker code LEI | FR0010331421 IPH 9695002Y8420ZB8HJE29 |
Disclaimer:
This press release contains certain forward-looking statements. Although the company believes its expectations are based on reasonable assumptions, these forward-looking statements are subject to numerous risks and uncertainties, which could cause actual results to differ materially from those anticipated. For a discussion of risks and uncertainties which could cause the company's actual results, financial condition, performance or achievements to differ from those contained in the forward-looking statements, please refer to the Risk Factors ("Facteurs de Risque") section of the Document de Reference prospectus filed with the AMF, which is available on the AMF website (www.amf-france.org) or on Innate Pharma's website.
This press release and the information contained herein do not constitute an offer to sell or a solicitation of an offer to buy or subscribe to shares in Innate Pharma in any country.
For additional information, please contact:
Investors Innate Pharma Dr. Markus Metzger / Danielle Spangler / Jérôme Marino Tel.: +33 (0)4 30 30 30 30 investors@innate-pharma.com | International Media Consilium Strategic Communications Mary-Jane Elliott / Jessica Hodgson Tel.: +44 (0)20 3709 5700 InnatePharma@consilium-comms.com |
French Media ATCG Press Marie Puvieux Mob: +33 (0)6 10 54 36 72 presse@atcg-partners.com |